The FDA today approved a subcutaneous induction regimen for AbbVie's Skyrizi (risankizumab-rzaa) in adults with moderately to ...
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS ...
Biopharma manufacturing today is being asked to move faster, accommodate increasingly complex modalities, and respond more ...
Gilead agrees to acquire an oral IL-23R inhibitor from PepStar, while Zymeworks licenses its DLL3-targeting T cell engager ...
Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s ...
Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure. President Trump’s Most-Favored Nation (MFN) initiative continues to ...
Alcon is acquiring Neurotech Pharmaceuticals to add the only FDA-approved MacTel cell therapy to its retina portfolio, while ...
In today’s Pharmaceutical Executive Daily, the FDA grants Ultomiris accelerated approval for adults with primary ...
Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab) has been approved in the U.S. to reduce proteinuria in adults ...
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health ...
ViiV Healthcare has announced that Deborah Waterhouse is stepping down as chief executive officer of ViiV Healthcare and ...
METiS TechBio announced a strategic collaboration with Eli Lilly and Company focused on researching and discovering novel lipid nanoparticle (LNP)-based delivery solutions designed to enable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results